Bauer Ferdinand
Chirurgia (Bucur). 2017 Mar-Apr;112(2):97-109. doi: 10.21614/chirurgia.112.2.97.
We notice an increasing frequency in the detection and evaluation of pancreatic cystic lesions (PCLs) over the last three decades. They show awide spectrum of imaging and clinical features. The diagnosis and discrimination of these lesions are very important because of the risk for concurrent or later development of malignancy. The main reason is the increased awareness of these lesions and the extensive use of cross-sectional imaging, an always improving technique (1). Commonly, PCLs are diagnosed incidentally during investigation for often unrelated and nonspecific abdominal complaints using state-of-the art abdominal imaging (CT, MRT). The term PCN denotes a histologically heterogeneous collection of neoplasms showing a wide spectrum of diagnoses, ranging from completely benign to potentially malignant, to carcinoma in situ, to frankly invasive and malignant (2,3). In 1978, Compagno and Oertel were the first to recognize the crucial distinction between the serous and the mucinous cystic neoplasms of the pancreas by explaining the importance of identifying the mucinous neoplasms because of their overt or latent malignant potential (4,5). Since then, the interest in PCLs increased markedly, especially so with the recognition of the importance and prevalence of intraductal papillary mucinous neoplasms (IPMNs). Nowadays, PCLs represent a common and often difficult challenge in clinical practice, because of the increase in their detection in asymptomatic patients and our still immature understanding of some aspects of their biologic behavior. Their important differences regarding their outcome and the fact of being increasingly often identified has put a special focus on these neoplasms by surgeons, pathologists, gastroenterologists, radiologists, and oncologists alike. Management of patients with PCNs can be challenging and varies considerably among the various subtypes of PCNs. Their treatment ranges from resection of malignant lesions, to resection and/or surveillance in the case of premalignant lesions, to simple observation in the case of benign or indolent lesions. Under these circumstances, the accurate classification of PCNs becomes crucial. Therapeutic decision making and classification rely mainly on the presenting symptoms and radiologic findings, often without actual histologic tissue. It is of extreme importance to identify suspicious features indicating potential or certain malignancy in order to select the appropriate treatment. The risk of overtreatment (unnecessary pancreatectomy) should he balanced carefully with the risk of under treatment (missing the opportunity to cure a potentially curable malignant or premalignant disease).
在过去三十年中,我们注意到胰腺囊性病变(PCLs)的检测和评估频率不断增加。它们表现出广泛的影像学和临床特征。由于存在并发或后期发生恶性肿瘤的风险,对这些病变的诊断和鉴别非常重要。主要原因是对这些病变的认识提高以及横断面成像技术的广泛应用,而横断面成像技术一直在不断改进(1)。通常,PCLs是在对通常无关且非特异性的腹部不适进行检查时,通过先进的腹部成像(CT、磁共振成像)偶然诊断出来的。术语PCN表示一组组织学上异质性的肿瘤,其诊断范围广泛,从完全良性到潜在恶性,再到原位癌,直至明显侵袭性和恶性(2,3)。1978年,康帕尼奥和奥特尔首次认识到胰腺浆液性和黏液性囊性肿瘤之间的关键区别,他们解释了识别黏液性肿瘤的重要性,因为其具有明显或潜在的恶性潜能(4,5)。从那时起,对PCLs的关注显著增加,尤其是在认识到导管内乳头状黏液性肿瘤(IPMNs)的重要性和患病率之后。如今,PCLs在临床实践中是一个常见且往往具有挑战性的问题,这是因为在无症状患者中其检出率增加,而我们对其生物学行为某些方面的理解仍不成熟。它们在预后方面的重要差异以及越来越频繁被发现这一事实,使得外科医生、病理学家、胃肠病学家、放射科医生和肿瘤学家等都特别关注这些肿瘤。PCN患者的管理可能具有挑战性,并且在PCN的各种亚型之间差异很大。其治疗范围从切除恶性病变,到对癌前病变进行切除和/或监测,再到对良性或惰性病变进行单纯观察。在这种情况下,PCN的准确分类变得至关重要。治疗决策和分类主要依赖于呈现的症状和影像学表现,通常没有实际的组织学组织。识别表明潜在或肯定恶性的可疑特征以选择合适的治疗方法极为重要。过度治疗(不必要的胰腺切除术)的风险应与治疗不足(错过治愈潜在可治愈的恶性或癌前疾病的机会)的风险仔细权衡。